Eli Lilly and Company logo

Eli Lilly and Company (LLY)

Market Open
9 Jun, 08:26
674. 00
-1
-0.15%
- Market Cap
104.2 P/E Ratio
5.2% Div Yield
9 Volume
6.64 Eps
675
Previous Close
Day Range
673.1 674
Year Range
615.2 886.5
Earnings results expected in 59 days

Summary

LLY trading today lower at €674, a decrease of 0.15% from yesterday's close, completing a monthly decrease of -4.8% or €34. Over the past 12 months, LLY stock lost -9.59%.
LLY pays dividends to its shareholders, with the most recent payment made on Mar 10, 2025. The next announced payment will be in In 1 day on Jun 10, 2025 for a total of €1.5.
The last earnings report, released on Apr 28, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports. The next scheduled earnings report is due on Aug 07, 2025.
The stock of the company had never split.
The company's stock is traded on 15 different exchanges and in various currencies, with the primary listing on NYSE (USD).
Want to track LLY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

LLY Chart

Chart

Empty chart
The chart has 2 Y axes displaying values, and values.
Loading, please wait...
End of interactive chart.
Rare Outflow Signals Hit Eli Lilly Shares

Rare Outflow Signals Hit Eli Lilly Shares

“Buy low, sell high” is a common investing mantra. It's easy to understand, but often hard to execute because emotion gets in the way.

Fxempire | 3 days ago
LLY Stock Too Cheap At $750?

LLY Stock Too Cheap At $750?

Question: Why would you pay 81 times earnings for AbbVie stock when you can buy LLY for a similar valuation of 76 times earnings? You wouldn't, especially when you consider three simple facts:

Forbes | 5 days ago
Eli Lilly : A Breakout Biotech Powerhouse With Room to Run

Eli Lilly : A Breakout Biotech Powerhouse With Room to Run

Eli Lilly NYSE: LLY has transformed from a steady pharmaceutical giant into one of Wall Street's standout growth stories—and it's not just hype. Powered by blockbuster drugs for diabetes and weight loss, a deep pipeline of next-generation treatments, and aggressive investment in future capacity, Lilly is rewriting what long-term success looks like in Big Pharma.

Marketbeat | 1 week ago

Eli Lilly and Company (LLY) FAQ

What is the stock price today?

The current price is €674.00.

On which exchange is it traded?

Eli Lilly and Company is listed on NYSE.

What is its stock symbol?

The ticker symbol is LLY.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

What is the earnings per share?

The EPS is 0.

When is the next earnings date?

The next earnings report will release on Aug 07, 2025.

Has Eli Lilly and Company ever had a stock split?

Eli Lilly and Company had 0 splits and the recent split was on Oct 16, 1997.

Eli Lilly and Company Profile

Drug Manufacturers - General Industry
Healthcare Sector
Mr. David A. Ricks CEO
XSTU Exchange
US5324571083 ISIN
US Country
47,000 Employees
14 Feb 2025 Last Dividend
16 Oct 1997 Last Split
13 Jan 1978 IPO Date

Overview

Eli Lilly and Company is a global leader in the discovery, development, and marketing of human pharmaceuticals. With a history dating back to 1876, the company has established itself as a key player in the pharmaceutical industry, offering a wide range of products aimed at treating a variety of conditions. Headquartered in Indianapolis, Indiana, Eli Lilly and Company has forged multiple collaborations with other pharmaceutical giants such as Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Genentech, Inc., Biologics, Inc., AbCellera Biologics Inc., and Chugai Pharmaceutical Co., Ltd., enhancing its product offerings and research capabilities across different therapeutic areas.

Products and Services

  • Diabetes Care

    Includes a comprehensive portfolio of insulin and other diabetes treatments: Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500. Additionally, the company offers Jardiance, Mounjaro, and Trulicity for managing type 2 diabetes.

  • Oncology

    Provides a range of products for cancer treatment, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio, focusing on different types of cancer and treatment approaches.

  • Immunology

    Olumiant is offered for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19. Taltz is available for treating plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis.

  • Digestive Diseases

    Omvoh is targeted at ulcerative colitis, reflecting the company's commitment to addressing gastrointestinal disorders.

  • Neurological Disorders

    Includes Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is provided for migraine prevention and treatment of episodic cluster headache.

  • Other Therapeutic Areas

    The company also offers Cialis for erectile dysfunction and benign prostatic hyperplasia; Forteo for osteoporosis treatment; Zepbound for obesity management; and Ebglyss for severe atopic dermatitis, showcasing Eli Lilly's diverse portfolio catering to various health conditions.

Contact Information

Address: Lilly Corporate Center
Phone: 317 276 2000